​​​​​​​PsA Treatment Options Expand

• by Kathryn Wighton

• March 9, 2026

Efficacy Comparison of Cycling Versus Transitioning to IL-17 Inhibitors Following Initial TNF Inhibitor Failure in Psoriatic Arthritis: A Multicenter Real-World Analysis

• by Alarico Ariani, Maddalena Larosa, Alberto Lo Gullo, Olga Addimanda, Romina Andracco, Patrizia Del Medico, Marino Paroli, Maria Chiara Ditto, Bernd Raffeiner, Aurora Ianniello, Francesca Ometto, Marta Priora, Aldo Biagio Molica Colella, Elena Bravi, Viviana Ravagnani, Alessandra Bezzi, Rosetta Vitetta, Palma Scolieri, Alessandro Volpe, Federica Lumetti, Antonella Farina, Francesco Girelli, Elisa Visalli, Francesca Serale, Eleonora Celletti, Veronica Franchina, Francesco Molica Colella, Giulio Ferrero, Fabio Mascella, Maria Cristina Focherini, Alessia Fiorenza, Guido Rovera, Cecilia Giampietro, Simone Bernardi, Natalia Mansueto, Dario Camellino, Rosalba Caccavale, Valeria Nucera, Myriam Di Penta, Emanuela Sabatini, Ilaria Platè, Adorni Giuditta, Eleonora Di Donato, Daniele Santilli, Gianluca Lucchini, Mirco Magnani, Gianluca Smerilli, Giorgio Amato, Francesco De Lucia, Ylenia Dal Bosco, Roberta Foti, Francesco Cipollone, Gerolamo Bianchi, Rosario Foti, Eugenio Arrigoni, Antonio Marchetta, Vincenzo Bruzzese, Gilda Sandri, Enrico Fusaro, Massimo Reta, Dilia Giuggioli, Antonio Marchesoni, Simone Parisi, Andrea Becciolini

• November 24, 2025

Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate

• by Eisa M. Hegazy, Eslam Abdelfattah Sadek, Shimaa Saber Ahmed

• March 18, 2026

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

• by Kathryn Wighton

• February 25, 2026

• 4 min